MediciNova, Inc. (MNOV) Stock

MediciNova, Inc. (MNOV) is a Healthcare stock trading at $1.40 (as of 2026-08-21), with a market capitalization of $68.66M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MediciNova, Inc. is a biopharmaceutical company developing small-molecule therapeutics for serious diseases with unmet needs, with an emphasis on conditions addressed in the United States. Its pipeline includes MN-166 (ibudilast), MN-221 (bedoradrine), MN-001 (tipelukast), and MN-029 (denibulin), and it has collaboration arrangements with multiple pharmaceutical companies.

Understand MediciNova, Inc.: how it makes money

MediciNova, Inc. develops novel small-molecule biopharmaceutical therapeutics, including ibudilast (MN-166), for serious diseases with unmet medical needs in the United States, seeking future returns if its pipeline programs progress to clinical and commercial milestones.

As a biopharmaceutical developer, MediciNova’s profit model is structurally tied to the success of its pipeline programs (such as MN-166) advancing through clinical development toward commercialization, rather than to near-term, product sales revenue.

Business quality (Weak): Limited disclosure in the provided dataset, with no official reportable segments or operating KPI labels available, so the investor view here relies on pipeline focus and the latest-quarter loss profile.

Bull case

  • Focused pipeline on neurological and other serious conditions: MN-166 (ibudilast) is being developed for neurological disorders with unmet needs, including primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as substance dependence and addiction.
  • Asset-driven upside if development progresses: The company’s pipeline programs, including MN-166 and MN-221 (bedor), are the core commercial opportunity, so positive clinical and regulatory progress could materially change the outlook.

Bear case

  • No segment and operating KPI visibility in the provided facts: The dataset includes no reportable segment breakdown and no operational metrics to track, making it harder to assess business momentum quarter to quarter.
  • Large operating losses in the latest reported quarter: For the period ending 2026-03-31, operating margin is reported as -1516.6, with revenue shown as 0.0B, indicating significant ongoing cost pressure relative to current revenue generation.
Valuation — source: SEC EDGAR (first-party)
Price$1.40
Market Cap$68.66M
Price / Book1.84
Price / Sales71.84
FCF Yield-29.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$409657.00
Net Margin-2928.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.45 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($8.58M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOYuichi Iwaki
Employees13
CountryUS
IPO Date2006-12-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Pliant Therapeutics, Inc. (PLRX)
  • Rein Therapeutics Inc. (RNTX)
  • Spero Therapeutics, Inc. (SPRO)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • XBiotech Inc. (XBIT)
  • OS Therapies Incorporated (OSTX)
  • Boundless Bio, Inc. (BOLD)
  • Cypherpunk Technologies Inc. (CYPH)
MNOV earnings history · MNOV institutional & insider holders · MNOV KPIs & operating metrics · MNOV financials · MNOV investor presentations & press releases · MNOV SEC filings · MNOV peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.